Rett Dialogue A.I CyberSecurity Scoring
06/12/2025
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for Rett Dialogue in 2026.
No incidents recorded for Rett Dialogue in 2026.
No incidents recorded for Rett Dialogue in 2026.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.
At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com. This site is intended for residents of the United States and Canada and their territories only. FLS: http://merck.us/3TKXNuZ
Sandoz is the global leader in generic and biosimilar medicines. Our Purpose is to pioneer access to medicines for patients globally. We are on a mission to drive innovation in the healthcare industry by freeing up resources sustainably and responsibly while continuing to address global health challenges such as antimicrobial resistance. We are present in more than 100 countries and our medicines serve some 500 million people every year. We have two main global businesses: Generics - divided between standard generics and complex generics - and Biosimilars. Read our community engagement guidelines: http://bit.ly/4ofoggc
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Latest updates, reports, and threat intel affecting the global network.
A vulnerability was detected in CodeAstro Student Attendance Management System 1.0. Impacted is an unknown function of the file /attendance-php/Admin/createStudents.php. Performing a manipulation of the argument admissionNumber results in sql injection. Remote exploitation of the attack is possible. The exploit is now public and may be used.
A security vulnerability has been detected in D-Link DCS-935L 1.10.01. This issue affects the function snprintf of the file /web/cgi-bin/greece/rhea of the component HTTP Handler. Such manipulation of the argument data leads to format string. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.
Nefteprodukttekhnika BUK TS-G Gas Station Automation System 2.9.1 through 2.10.2 on Linux contains an Improper Authentication vulnerability (CWE-287) in the system configuration module. The /php/ajax-login.php endpoint returns userid=1 (administrator) in response to any HTTP POST request that supplies arbitrary credentials (e.g., action=dologin&login=<any_value>&pwd=<any_value>), and subsequent privileged endpoints under /php/ajax-main.php and /modules/* do not validate a server-side session. A remote unauthenticated attacker can invoke any administrative action exposed by the configuration module, including reading and modifying user rules, fuel tank gauges, fuel dispensers, relays, cash registers, bank terminals, fuel cards, price and customer displays, cash collection, and pricing rules.
SQL Injection in reports/catalogue_out.pl in Koha Community Koha through 22.11.37, 23.x, 24.x before 24.11.16, 25.05.x before 25.05.11, 25.11.x before 25.11.05, 26.05.x before 26.05.01, and 26.11.x before 26.11.00 allows an authenticated staff user with the Reports module flag to read arbitrary data from the Koha application database via the Filter URL parameter when the Criteria parameter matches /branchcode/. The vulnerable sink in sub calculate concatenates the unmodified Filter request parameter directly into a LIKE clause of the auxiliary $strsth2 statement and executes it via DBI without bound parameters: my $f = @$filters[0]; $f =~ s/\*/%/g; $strsth2 .= " AND $column LIKE '$f' "; This enables error-based SQL injection (e.g., via EXTRACTVALUE) and full read access to sensitive tables including borrowers (password hashes, 2FA secrets, PII), borrower_password_recovery, api_keys, and sessions. Proof of concept (error-based, single request): GET /cgi-bin/koha/reports/catalogue_out.pl?do_it=1&output=screen&Limit=10&Criteria=branchcode&Filter=x'+AND+EXTRACTVALUE(1,CONCAT(0x7e,VERSION(),0x7c,USER(),0x7c,DATABASE(),0x7e))--+- Cookie: CGISESSID=<LIBRARIAN_SESSION> The response body contains the DBI exception leaking the MariaDB version, database user, client IP, and database name, after which arbitrary data can be paged out using LIMIT n,1 / SUBSTRING(...). The vulnerable sink was introduced in commit 6bb77ae3e4 (2008-07-09); CVE-2015-4633 patched the same class in sibling files but did not generalise the fix to reports/catalogue_out.pl. Fixed in Koha 22.11.38, 24.11.16, 25.05.11, 25.11.05, 26.05.01, and 26.11.00 by replacing the raw concatenation with a parameterised placeholder.
The Online Scheduling and Appointment Booking System – Bookly plugin for WordPress is vulnerable to Stored Cross-Site Scripting via the 'bookly-customer-full-name' cookie in versions up to, and including, 27.2 due to insufficient input sanitization and output escaping. This makes it possible for unauthenticated attackers to inject arbitrary web scripts in pages that will execute whenever a user accesses an injected page. Exploitation requires 'Remember personal information in cookies' setting to be enabled (disabled by default).
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.